Carnitine uptake defect (primary carnitine deficiency)
Log in to starLast updated Nov 4, 2026
A child presents with cardiomyopathy and hypoglycemia. Plasma carnitine is severely reduced. The condition is completely treatable with carnitine supplementation.
AR; SLC22A5 (OCTN2, the plasma membrane carnitine transporter). Biallelic loss-of-function variants stop cells and kidney tubules from taking up carnitine.
OCTN2, encoded by SLC22A5, is the organic cation transporter that carries carnitine into cells of the kidney, heart, skeletal muscle, and many other tissues. Carnitine is needed to move long-chain fatty acids from the cytoplasm into mitochondria for beta-oxidation, the main fuel of liver, heart, and skeletal muscle during fasting.
Loss of function has three effects at once: the kidney cannot reclaim filtered carnitine (urinary wasting), plasma carnitine falls, and cells hold too little carnitine. Fatty acid oxidation then fails:
- Glucose is consumed without being replaced by gluconeogenesis, giving hypoglycemia during fasting or illness.
- Fat released from adipose tissue collects in liver, skeletal muscle, and heart, giving hepatic steatosis and myopathy.
- The heart develops dilated cardiomyopathy, and a shortened QT interval can lead to arrhythmia; both can be fatal before diagnosis.
Nonsense and frameshift variants are more frequent in symptomatic people and missense variants in asymptomatic ones, but no firm genotype-phenotype correlation exists. Treatment replaces what is missing, with high-dose oral carnitine. A low newborn C0 can instead reflect the mother's own carnitine deficiency, which is why the mother is tested too.
Part of the carnitine shuttle.
Carnitine shuttle, which carries long-chain fatty acids into mitochondria for beta-oxidation.
carnitine in blood and kidney filtrate → OCTN2 carnitine transporter, plasma membrane (the block) → carnitine inside the cell → CPT1A forms long-chain acylcarnitine → CACT → CPT2 → long-chain acyl-CoA in the matrix → beta-oxidation
- Accumulates: fat in liver, heart, and skeletal muscle; carnitine is lost in urine rather than stored, so plasma free carnitine (C0) is very low.
- Missing: carnitine inside cells, so long-chain fat cannot enter mitochondria and fasting brings hypoketotic hypoglycemia.
- Workbook: 5.D. Disorders of the carnitine shuttle system
- Cardiomyopathy (dilated)
- Hypoglycemia, hepatomegaly
- Skeletal myopathy
- Very low plasma carnitine
- On RUSP
- Newborn screening (RUSP) acylcarnitine profile: very low free carnitine (C0), the key marker (opposite of CPT1A, which has high C0)
- A low newborn C0 may reflect maternal carnitine deficiency, so the mother's plasma carnitine should also be checked
- Markedly reduced plasma total and free carnitine; reduced carnitine transport in cultured fibroblasts
- Confirmatory SLC22A5 molecular testing
- Oral carnitine (dramatic response, prevents cardiomyopathy)
NBS: Low C0 (free carnitine). On the newborn screening acylcarnitine profile, low C0 (free carnitine) is the key marker for carnitine uptake deficiency. Contrast with CPT1A, which has high C0.
"CUD is CUrable": carnitine uptake defect is one of the most treatable inborn errors of metabolism. Oral carnitine supplementation produces a dramatic response and prevents life-threatening cardiomyopathy.
In CUD, chemistries are ubiquitously down: low ketones, low glucose, and low free carnitine (C0) in plasma, with cardiac and skeletal muscle dysfunction.
